BioDelivery, Endo deal

BioDelivery granted Endo exclusive, worldwide rights to develop and commercialize BEMA Buprenorphine to treat chronic pain. BioDelivery will receive $30 million up front, and is eligible for up to $95 million in developmental milestones and $55 million in commercial milestones, plus tiered, mid to upper teen royalties on U.S. net sales. ...